THERAPY DOSSIER · th-0f7016b2c79e

PJ-34

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21623955 ↗2011Mixed findings

Studies of locomotor network neuroprotection by the selective poly(ADP-ribose) polymerase-1 inhibitor PJ-34 against excitotoxic injury to the rat spinal cord in vitro.

RatSpinal cord injuryUnspecifiedWistarBath application (in vitro)60 microM

Model: In vitro kainate excitotoxic injury to spinal cord locomotor networks (models acute spinal injury)

The PARP-1 inhibitor PJ-34 preserved spinal cord histology after excitotoxic injury but restored fictive locomotion only when the excitotoxic insult was moderate.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…